Increasing MAT Engagement With Financial Incentives
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04585399|
Recruitment Status : Recruiting
First Posted : October 14, 2020
Last Update Posted : November 24, 2021
|Condition or disease||Intervention/treatment||Phase|
|Opioid-use Disorder||Behavioral: Contingency management||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Two group, randomized controlled trial.|
|Masking:||Double (Care Provider, Outcomes Assessor)|
|Masking Description:||Participants will only told if they are assigned to the contingency management group because there are different procedures for those individuals. The care providers will not know which participants are in the control group but they may know when people are in the CM group because extra urine screens will be collected and they will be scheduled for rides.|
|Official Title:||Increasing MAT Engagement With Contingency Management Among Individuals With Opioid Use Disorder in an ED Bridge Program|
|Actual Study Start Date :||January 27, 2020|
|Estimated Primary Completion Date :||January 26, 2023|
|Estimated Study Completion Date :||January 26, 2023|
Experimental: Contingency Management
Participants in this arm of the study will receive financial incentives for attending their buprenorphine appointments and for being clean from other opioids. Participants in this group will also have up to two rides per week paid for to attend bup appointments.
Behavioral: Contingency management
Financial incentives for attending bup appointments and demonstrating opioid abstinence. Rides will also be provided for up to two clinic visits per week.
No Intervention: Standard Care
Participants in this group will be treatment as usual and will not receive any incentives for attending their bup appointments or for being opioid abstinent.
- Attendance at first scheduled clinic appointment [ Time Frame: 1 week ]We will track attendance at participant's first scheduled BUP appointment after being bridged from the ED
- Percentage of sessions where buprenorphine positive urine results was recorded [ Time Frame: 3-months ]Urine-verified buprenorphine
- Percentage of sessions where opioid free urine results were recorded [ Time Frame: 3-months ]Urine-verified opioid abstinence
- Treatment acceptability [ Time Frame: 3-months ]Participants will evaluate the treatment at the end.
- Delay discounting as a correlate of opioid-free urine test results and buprenorphine-positive results [ Time Frame: 3-months ]Delay discounting will be evaluated, using the brief, five question delay discounting procedure and will be correlated with urine results determining opioid abstinence and buprenorphine adherence.
- Opioid demand as a correlate of opioid-free urine test results and buprenorphine-positive results [ Time Frame: 3-months ]The opioid purchasing task will be used to evaluate opioid demand and will be correlated with urine results determining opioid abstinence and buprenorphine adherence.
- Substance-free activities as a correlate of opioid-free urine test results and buprenorphine-positive results [ Time Frame: 3-months ]A modified Pleasant Events Scale survey will be used to evaluate access to, and enjoyment from, substance-free activities and the results will be correlated with urine results determining opioid abstinence and buprenorphine adherence.
- Neurological Soft Signs correlate with treatment success [ Time Frame: 3-months ]Participants will complete a drawing task that has been correlated with other substance use treatment outcomes in the past.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04585399
|Contact: Bethany Raiff, PhD||856-256-4500 ext email@example.com|
|United States, New Jersey|
|Cooper University Hospital||Recruiting|
|Camden, New Jersey, United States, 08108|
|Contact: Bethany Raiff, PhD 856-256-4500 ext 5-3782 firstname.lastname@example.org|
|Principal Investigator: Bethany Raiff, PhD|